Michael Utz has joined Madrigal Pharmaceuticals as Senior Director, Commercial Development – Marketing, bringing 30 years of pharmaceutical and biotechnology sales and marketing experience to the company as it builds out commercialization of its MASH treatment.
About Michael Utz
Utz joins Madrigal from Teva Pharmaceuticals, where he spent nearly a decade in senior marketing leadership roles of increasing scope, most recently as Senior Director, Global Marketing, Launch Readiness for Olanzapine LAI. He previously served as Senior Director, Global Brand Lead for AJOVY, Senior Director, Global Biologics Commercial, Senior Director, Global Early Pipeline Assets and LCM, and Senior Director, Global Respiratory Marketing.
Before Teva, Utz spent nearly 13 years at EMD Serono, rising from Director of Marketing, US Neurology, to Head of New Product Planning and ultimately Vice President, Global New Product Planning. He began his career at Eli Lilly and Company, first as a Sales Representative and later as a Marketing Associate.
Utz holds a Bachelor of Arts in Economics from Villanova University.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company headquartered in Conshohocken, Pennsylvania, dedicated to developing treatments for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver disease. The company’s lead therapy, resmetirom, became the first approved medication for MASH when it received FDA approval in 2024, making Madrigal the first company to bring a MASH treatment to the U.S. market; the therapy has since gained approval in the European Union as well. Founded in 2008 by Dr. Rebecca Taub, Madrigal has grown from a small research team into a fully integrated pharmaceutical organization with hundreds of employees across the United States and Europe, and maintains an active pipeline with more than 10 additional programs in development.
